Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer

摘要

Disclosed is the use of pharmaceutically effective amounts of hydralazine and valproic acid or a salt thereof together in the manufacture of a medicament kit for the treatment of cancer wherein the medicament kit is administrable together with a chemotherapeutic agent or radiotherapy.